We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.08%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$810M
AUM Growth
+$146M
Cap. Flow
+$85.4M
Cap. Flow %
10.54%
Top 10 Hldgs %
36.98%
Holding
72
New
23
Increased
22
Reduced
9
Closed
15

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$32.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$20.4M
3
INCY icon
Incyte
INCY
+$19.5M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$18.9M
5
AGN
Allergan Inc
AGN
+$18.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$38.7M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$28.8M
3
STJ
St Jude Medical
STJ
+$25.8M
4
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$23.3M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
2 Miscellaneous 12.08%
3 Consumer Staples 1.18%
4 Technology 0.55%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IHF icon
51
iShares US Healthcare Providers ETF
IHF
$1.23B
$280K 0.03%
+15,000
New +$270K
REGN icon
52
Regeneron Pharmaceuticals
REGN
$81.8B
$275K 0.03%
1,000
-79,400
-99% -$22.8M
PRTA icon
53
Prothena Corp
PRTA
$479M
$241K 0.03%
+9,100
New +$228K
DYAX
54
DELISTED
DYAX CORPORATION
DYAX
$188K 0.02%
+25,000
New +$190K
VIRX
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$166K 0.02%
+167
New +$173K
MRK icon
56
Merck
MRK
$366B
$120K 0.01%
2,515
+524
+26% +$24K
AGIO icon
57
Agios Pharmaceuticals
AGIO
$1.99B
– –
-53,100
Closed -$1.49M
AMGN icon
58
Amgen
AMGN
$234B
– –
-345,700
Closed -$38.7M
BKD icon
59
Brookdale Senior Living
BKD
$2.8B
– –
-757,800
Closed -$19.9M
NUWE icon
60
Nuwellis
NUWE
$2.82M
– –
0
– -$5.45M
PACB icon
61
Pacific Biosciences
PACB
$435M
– –
-1,574,379
Closed -$8.71M
PGEN icon
62
Precigen
PGEN
$2.49B
– –
-213,033
Closed -$4.82M
PRGO icon
63
Perrigo
PRGO
$2.01B
– –
-1,700
Closed -$210K
SNDA icon
64
Sonida Senior Living
SNDA
$1.8B
– –
-39,820
Closed -$12.6M
VRTX icon
65
Vertex Pharmaceuticals
VRTX
$137B
– –
-108,262
Closed -$8.21M
VSTM icon
66
Verastem
VSTM
$654M
– –
-2,583
Closed -$386K
ZTS icon
67
Zoetis
ZTS
$32B
– –
-465,900
Closed -$14.5M
ARIA
68
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-1,264,009
Closed -$23.3M
CTRX
69
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
– –
-508,100
Closed -$23.3M
CBST
70
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-452,600
Closed -$28.8M
ARTC
71
DELISTED
ARTHROCARE CORP
ARTC
– –
-342,759
Closed -$12.2M
RPRX
72
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-10,500
Closed -$281K
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2013 Portfolio in Review

As of Q4 2013, Redmile Group held 72 positions worth $810M, up 22% from $664M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Redmile Group deployed $85.4M of net new capital in Q4 2013, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 378,669 shares worth $34.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was St Jude Medical, an estimated $25.8M trimmed.

  • Redmile Group's largest Q4 2013 buy was Zimmer Biomet: 378,669 shares worth $34.3M.
  • Redmile Group added most to Allergan Inc in Q4 2013, an estimated $18.8M increase.
  • Redmile Group's biggest Q4 2013 reduction was St Jude Medical, cutting an estimated $25.8M.
  • Redmile Group fully exited Amgen in Q4 2013, selling an estimated $38.7M.
  • Redmile Group's ten largest holdings make up 37% of its $810M portfolio in Q4 2013.
  • Redmile Group opened 23 new positions and closed 15 in Q4 2013.
  • Redmile Group's portfolio value rose 22% quarter-over-quarter to $810M.

Based on Redmile Group's 13F filing for Q4 2013, filed 14 Feb 2014.